Corpus Intelligence IC Memo — MONROE COMMUNITY HOSPITAL 2026-04-26 07:38 UTC
IC Memo — MONROE COMMUNITY HOSPITAL
Investment Committee Memorandum | NY | 5 beds | Grade D | EBITDA uplift $5.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MONROE COMMUNITY HOSPITAL

CCN 330403 | MONROE, NY | 5 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

MONROE COMMUNITY HOSPITAL is a 5-bed community hospital in MONROE, NY with $70.5M in net patient revenue and a -16.2% operating margin. The hospital serves a payer mix of 0.0% Medicare, 0.0% Medicaid, and 100.0% commercial.

Thesis: Turnaround. Our ML models identify $5.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -16.2% to -8.8% (+736bps).

Net Revenue HCRIS$70.5M
Current EBITDA COMPUTED$-11.4M
Operating Margin COMPUTED-16.2%
Occupancy HCRISnan%
Revenue / Bed COMPUTED$14.1M
Net-to-Gross HCRIS10.5%
Distress Probability MLnan%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
50
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -16.2% places it above the state median. Among 50 size-comparable peers (2-10 beds), the median margin is -8.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (2-10), prioritizing same-state peers. 50 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MONROE COMMUNITY HOSPITAL (Target)NY5$70.5M-16.2%
FRANCISCAN HEALTH HAMMONDIN10$117.7M-4.3%
OCONTO HOSPITAL & MEDICAL CENTWI10$80.4M1.1%
SUMMIT PACIFIC MEDICAL CENTERWA10$73.6M9.1%
PHYSICIANS MEDICAL CENTERIN10$60.0M24.9%
SAMUEL SIMMONDS MEMORIAL HOSPIAK10$57.8M-50.0%
JOYCE EISENBERG KEEFER MEDICALCA10$52.9M18.8%
PARK PLACE SURGERY CENTERLA10$51.6M15.4%
JONES REGIONAL MEDICAL CTRIA10$43.5M0.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.5M+210bp18mo
Cost to Collect4.5%2.5%$1.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$858K+122bp9mo
Clean Claim Rate88.0%96.0%$45K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.5M
Cost to Collect
$1.4M
Denial Rate Reduction
$1.4M
A/R Days Reduction
$858K
Clean Claim Rate
$45K
Total EBITDA Uplift$5.2M
Current EBITDA$-11.4M
+ RCM Uplift+$5.2M
Pro Forma EBITDA$-6.2M
Current Margin-16.2%
Pro Forma Margin-8.8%
WC Released (1x)$2.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-17.6M$-23.4M0.00x-100.0%
Base (11x exit)10.0x11.0x$-17.6M$-31.5M0.00x-100.0%
Bull Case9.0x11.0x$-15.8M$-20.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-15.8M$-26.5M0.00x-100.0%
Bear Case11.0x10.0x$-19.3M$-43.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-19.3M$-54.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 50 hospitals with 2-10 beds
  • Same-state prioritization (n=2)
  • Comp margins: P25=-35.5% / P50=-8.7% / P75=4.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.